Update on the molecular pathogenesis of pancreatic tumors other than common ductal adenocarcinoma

Pancreatology

Volumn 9, Issue 1-2, 2009, Pages 25-33

  Antonello, D ^a   Gobbo, S ^a   Corbo, V ^a   Sipos, B ^b   Lemoine, N R ^c   Scarpa, A ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF KIEL   (Germany)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Pancreas; Pathogenesis; Tumor

Indexed keywords

ACINAR CELL CARCINOMA; CANCER CLASSIFICATION; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MUCINOUS CYSTIC TUMOR; PANCREAS ENDOCRINE TUMOR; PANCREAS TUMOR; PANCREATOBLASTOMA; PRIORITY JOURNAL; REVIEW; SEROUS CYSTIC TUMOR; SOLID PSEUDOPAPILLARY TUMOR;

EID: 57449106363     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000178872     Document Type: Article

References (121)

1. Klöppel G, Hruban RH, Longnecker DS, Adler G, Kern SE, Partanen TJ: Ductal adenocarcinoma of the pancreas; in Hamilton SR, Aaltonen LA (eds): Pathology and Genetics of Tumours of the Digestive System. WHO Classification of Tumours. Lyon, IARC Press, 2000.
2. Klöppel G et al: Classification of pancreatic neoplasms and their genetics; in Gress T, Neoptolemos J, Lemoine N, Real F (eds): Exocrine Pancreas Cancer. Ulm, The European Pancreatic Cancer-Research Cooperative, 2004.
3. Zamboni G, Klöppel G, Hruban RH, Longnecker DS, Adler G: Mucinous cystic neoplasms of the pancreas; in Hamilton SR, Aaltonen LA (eds): Pathology and Genetics of Tumours of the Digestive System. WHO Classification of Tumours. Lyon, IARC Press, 2000.
4. Terris B, Ponsot P, Paye F, Hammel P, Sauvanet A, Molas G, et al: Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol 2000; 24: 1372-1377.
5. Sohn TA, Yeo CJ, Cameron JL, Hruban RH, Fukushima N, Campbell KA, et al: Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 2004; 239: 788-797; discussion 797-799.
6. Furukawa T, Kloppel G, Volkan Adsay N, Albores- Saavedra J, Fukushima N, Horii A, et al: Classification of types of intraductal papillary- mucinous neoplasm of the pancreas: a consensus study. Virchows Arch 2005; 447: 794-799.
7. Luttges J, Zamboni G, Longnecker D, Kloppel G: The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma. Am J Surg Pathol 2001; 25: 942-948.
8. Adsay NV, Merati K, Basturk O, Iacobuzio- Donahue C, Levi E, Cheng JD, et al: Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an 'intestinal' pathway of carcinogenesis in the pancreas. Am J Surg Pathol 2004; 28: 839-848.
9. Miyasaka Y, Nagai E, Yamaguchi H, Fujii K, Inoue T, Ohuchida K, et al: The role of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res 2007; 13: 4371- 4377.
10. Furukawa T: Molecular genetics of intraductal papillary-mucinous neoplasms of the pancreas. J Hepatobiliary Pancreat Surg 2007; 14: 233-237.
11. Satoh K, Shimosegawa T, Moriizumi S, Koizumi M, Toyota T: K-ras mutation and p53 protein accumulation in intraductal mucinhypersecreting neoplasms of the pancreas. Pancreas 1996; 12: 362-368.
12. Kitago M, Ueda M, Aiura K, Suzuki K, Hoshimoto S, Takahashi S, et al: Comparison of K-ras point mutation distributions in intraductal papillary-mucinous tumors and ductal adenocarcinoma of the pancreas. Int J Cancer 2004; 110: 177-182.
13. Sessa F, Solcia E, Capella C, Bonato M, Scarpa A, Zamboni G, et al: Intraductal papillary- mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Arch 1994; 425: 357-367.
14. Semba S, Moriya T, Kimura W, Yamakawa M: Phosphorylated Akt/PKB controls cell growth and apoptosis in intraductal papillary- mucinous tumor and invasive ductal adenocarcinoma of the pancreas. Pancreas 2003; 26: 250-257.
15. House MG, Guo M, Iacobuzio-Donahue C, Herman JG: Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis 2003; 24: 193-198.
16. Furukawa T, Fujisaki R, Yoshida Y, Kanai N, Sunamura M, Abe T, et al: Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Mod Pathol 2005; 18: 1034-1042.
17. Inoue H, Furukawa T, Sunamura M, Takeda K, Matsuno S, Horii A: Exclusion of SMAD4 mutation as an early genetic change in human pancreatic ductal tumorigenesis. Genes Chromosomes Cancer 2001; 31: 295-299.
18. Iacobuzio-Donahue CA, Klimstra DS, Adsay NV, Wilentz RE, Argani P, Sohn TA, et al: Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol 2000; 157: 755-761.
19. Sato N, Rosty C, Jansen M, Fukushima N, Ueki T, Yeo CJ, et al: STK11/LKB1 Peutz- Jeghers gene inactivation in intraductal papillary- mucinous neoplasms of the pancreas. Am J Pathol 2001; 159: 2017-2022.
20. Xu S, Furukawa T, Kanai N, Sunamura M, Horii A: Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J Hum Genet 2005; 50: 159-167.
21. Sato N, Goggins M: Epigenetic alterations in intraductal papillary mucinous neoplasms of the pancreas. J Hepatobiliary Pancreat Surg 2006; 13: 280-285.
22. Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruszniewski P, et al: Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol 2002; 160: 1745- 1754.
23. Sato N, Fukushima N, Maitra A, Iacobuzio- Donahue CA, van Heek NT, Cameron JL, et al: Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am J Pathol 2004; 164: 903-914.
24. Sato N, Matsubayashi H, Abe T, Fukushima N, Goggins M: Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin Cancer Res 2005; 11: 4681- 4688.
25. Ohuchida K, Mizumoto K, Fujita H, Yamaguchi H, Konomi H, Nagai E, et al: Sonic hedgehog is an early developmental marker of intraductal papillary mucinous neoplasms: clinical implications of mRNA levels in pancreatic juice. J Pathol 2006; 210: 42- 48.
26. Liu MS, Yang PY, Yeh TS: Sonic hedgehog signaling pathway in pancreatic cystic neoplasms and ductal adenocarcinoma. Pancreas 2007; 34: 340-346.
27. Jang KT, Lee KT, Lee JG, Choi SH, Heo JS, Choi DW, et al: Immunohistochemical expression of Sonic hedgehog in intraductal papillary mucinous tumor of the pancreas. Appl Immunohistochem Mol Morphol 2007; 15: 294-298.
28. Yamaguchi H, Inoue T, Eguchi T, Miyasaka Y, Ohuchida K, Mizumoto K, et al: Fascin overexpression in intraductal papillary mucinous neoplasms (adenomas, borderline neoplasms, and carcinomas) of the pancreas, correlated with increased histological grade. Mod Pathol 2007; 20: 552-561.
29. Schonleben F, Qiu W, Ciau NT, Ho DJ, Li X, Allendorf JD, et al: PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res 2006; 12: 3851-3855.
30. Hashimoto Y, Murakami Y, Uemura K, Hayashidani Y, Sudo T, Ohge H, et al: Detection of human telomerase reverse transcriptase (hTERT) expression in tissue and pancreatic juice from pancreatic cancer. Surgery 2008; 143: 113-125.
31. Kanno A, Satoh K, Kimura K, Hirota M, Umino J, Masamune A, et al: The expression of MUC4 and MUC5AC is related to the biologic malignancy of intraductal papillary mucinous neoplasms of the pancreas. Pancreas 2006; 33: 391-396.
32. Zamboni G, Scarpa A, Bogina G, Iacono C, Bassi C, Talamini G, et al: Mucinous cystic tumors of the pancreas: clinicopathological features, prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol 1999; 23: 410-422.
33. Wilentz RE, Albores-Saavedra J, Zahurak M, Talamini MA, Yeo CJ, Cameron JL, et al: Pathologic examination accurately predicts prognosis in mucinous cystic neoplasms of the pancreas. Am J Surg Pathol 1999; 23: 1320-1327.
34. Fukushima N, Fukayama M: Mucinous cystic neoplasms of the pancreas: pathology and molecular genetics. J Hepatobiliary Pancreat Surg 2007; 14: 238-242.
35. Luttges J, Feyerabend B, Buchelt T, Pacena M, Kloppel G: The mucin profile of noninvasive and invasive mucinous cystic neoplasms of the pancreas. Am J Surg Pathol 2002; 26: 466-471.
36. Sawai H, Okada Y, Funahashi H, Matsuo Y, Tanaka M, Manabe T: Immunohistochemical analysis of molecular biological factors in intraductal papillary-mucinous tumors and mucinous cystic tumors of the pancreas. Scand J Gastroenterol 2004; 39: 1159-1165.
37. Jimenez RE, Warshaw AL, Z'Graggen K, Hartwig W, Taylor DZ, Compton CC, et al: Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann Surg 1999; 230: 501-509; discussion 509-511.
38. Kim SG, Wu TT, Lee JH, Yun YK, Issa JP, Hamilton SR, et al: Comparison of epigenetic and genetic alterations in mucinous cystic neoplasm and serous microcystic adenoma of pancreas. Mod Pathol 2003; 16: 1086- 1094.
39. Gerdes B, Wild A, Wittenberg J, Barth P, Ramaswamy A, Kersting M, et al: Tumor-suppressing pathways in cystic pancreatic tumors. Pancreas 2003; 26: 42-48.
40. Izeradjene K, Combs C, Best M, Gopinathan A, Wagner A, Grady WM, et al: Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 2007; 11: 229-243.
41. Fukushima N, Sato N, Yeo CJ, Cameron JL, et al: Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays. Oncogene 2004; 23: 9042-9051.
42. Ishiguro H, Kato K, Kishimoto T, Nagai Y, Takahashi T, Sasano H, et al: Expression of steroidogenic enzymes by luteinizing cells in the ovarian-type stroma of a mucin-producing cystic tumour of the pancreas. Histopathology 2003; 43: 97-98.
43. Sorio C, Capelli P, Lissandrini D, Moore PS, Balzarini P, Falconi M, et al: Mucinous cystic carcinoma of the pancreas: a unique cell line and xenograft model of a preinvasive lesion. Virchows Arch 2005; 446: 239-245.
44. Capella C, Solcia E, et al: Serous cystic neoplasms of the pancreas; in Hamilton SR, Aaltonen LA (eds): Pathology and Genetics of Tumours of the Digestive System. WHO Classification of Tumours. Lyon, IARC Press, 2000.
45. Compton CC: Serous cystic tumors of the pancreas. Semin Diagn Pathol 2000; 17: 43- 55.
46. George DH, Murphy F, Michalski R, Ulmer BG: Serous cystadenocarcinoma of the pancreas: a new entity? Am J Surg Pathol 1989; 13: 61-66.
47. Kosmahl M, Seada LS, Janig U, Harms D, Kloppel G: Solid-pseudopapillary tumor of the pancreas: its origin revisited. Virchows Arch 2000; 436: 473-480.
48. Kosmahl M, Wagner J, Peters K, Sipos B, Kloppel G: Serous cystic neoplasms of the pancreas: an immunohistochemical analysis revealing alpha-inhibin, neuron-specific enolase, and MUC6 as new markers. Am J Surg Pathol 2004; 28: 339-346.
49. Hoorens A, Prenzel K, Lemoine NR, Kloppel G: Undifferentiated carcinoma of the pancreas: analysis of intermediate filament profile and Ki-ras mutations provides evidence of a ductal origin. J Pathol 1998; 185: 53-60.
50. Ji Y, Wang XN, Lou WH, Sujie A, Tan YS, Jin DY: Serous cystic neoplasms of the pancreas: a clinicopathologic and immunohistochemical analysis. Chin J Dig Dis 2006; 7: 39-44.
51. Moore PS, Orlandini S, Zamboni G, Capelli P, Rigaud G, Falconi M, et al: Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer 2001; 84: 253-262.
52. Moore PS, Zamboni G, Brighenti A, Lissandrini D, Antonello D, Capelli P, et al: Molecular characterization of pancreatic serous microcystic adenomas: evidence for a tumor suppressor gene on chromosome 10q. Am J Pathol 2001; 158: 317-321.
53. Gumbs AA, Moore PS, Falconi M, Bassi C, Beghelli S, Modlin I, et al: Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms. J Surg Oncol 2002; 81: 45-53; discussion 54.
54. Klöppel G, Perren A, PU. H: The gastroenteropancreatic neuroendocrine cell system and its tumors. The WHO classification. Ann N Y Acad Sci 2004; 1014: 13-27.
55. Solcia E, Kloppel G, LH S: Histological Typing of Endocrine Tumours. New York, Springer, 2001.
56. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, et al: The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998; 17: 5001-5014.
57. Muscarella P, Melvin WS, Fisher WE, Foor J, Ellison EC, Herman JG, et al: Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. Cancer Res 1998; 58: 237-240.
58. House MG, Schulick RD: Endocrine tumors of the pancreas. Curr Opin Oncol 2006; 18: 23-29.
59. Bartsch DK, Kersting M, Wild A, Ramaswamy A, Gerdes B, Schuermann M, et al: Low frequency of p16(INK4a) alterations in insulinomas. Digestion 2000; 62: 171-177.
60. Cupisti K, Hoppner W, Dotzenrath C, Simon D, Berndt I, Roher HD, et al: Lack of MEN1 gene mutations in 27 sporadic insulinomas. Eur J Clin Invest 2000; 30: 325-329.
61. Goebel SU, Heppner C, Burns AL, Marx SJ, Spiegel AM, Zhuang Z, et al: Genotype/phenotype correlation of multiple endocrine neoplasia type 1 gene mutations in sporadic gastrinomas. J Clin Endocrinol Metab 2000; 85: 116-123.
62. Moore PS, Missiaglia E, Antonello D, Zamo A, Zamboni G, Corleto V, et al: Role of disease- causing genes in sporadic pancreatic endocrine tumors: MEN1 and VHL. Genes Chromosomes Cancer 2001; 32: 177-181.
63. Wang EH, Ebrahimi SA, Wu AY, Kashefi C, Passaro E Jr, Sawicki MP: Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. Cancer Res 1998; 58: 4417- 4420.
64. Zhuang Z, Vortmeyer AO, Pack S, Huang S, Pham TA, Wang C, et al: Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 1997; 57: 4682-4686.
65. Rigaud G, Missiaglia E, Moore PS, Zamboni G, Falconi M, Talamini G, et al: High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Res 2001; 61: 285-292.
66. Perren A, Komminoth P, PU H: Molecular genetics of gastroenteropancreatic endocrine tumors. Ann N Y Acad Sci 2004; 1014: 199-208.
67. Nagano Y, Kim do H, Zhang L, White JA, Yao JC, Hamilton SR, et al: Allelic alterations in pancreatic endocrine tumors identified by genome-wide single nucleotide polymorphism analysis. Endocr Relat Cancer 2007; 14: 483-492.
68. Rigaud G, Moore PS, Zamboni G, Orlandini S, Taruscio D, Paradisi S, et al: Allelotype of pancreatic acinar cell carcinoma. Int J Cancer 2000; 88: 772-777.
69. Hahn SA, Seymour AB, Hoque AT, Schutte M, da Costa LT, Redston MS, et al: Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res 1995; 55: 4670- 4675.
70. Chung DC, Brown SB, Graeme-Cook F, Tillotson LG, Warshaw AL, Jensen RT, et al: Localization of putative tumor suppressor loci by genome-wide allelotyping in human pancreatic endocrine tumors. Cancer Res 1998; 58: 3706-3711.
71. Jonkers YM, Claessen SM, Perren A, Schmitt AM, Hofland LJ, de Herder W, et al: DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients. Endocr Relat Cancer 2007; 14: 769-779.
72. Capurso G, Lattimore S, Crnogorac-Jurcevic T, Panzuto F, Milione M, Bhakta V, et al: Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr Relat Cancer 2006; 13: 541-558.
73. Hansel DE, Rahman A, House M, Ashfaq R, Berg K, Yeo CJ, et al: Met proto-oncogene and insulin-like growth factor binding protein
74. overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. Clin Cancer Res 2004; 10: 6152-6158.
75. Maitra A, Hansel DE, Argani P, Ashfaq R, Rahman A, Naji A, et al: Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays. Clin Cancer Res 2003; 9: 5988- 5995.
76. Couvelard A, Hu J, Steers G, O'Toole D, Sauvanet A, Belghiti J, et al: Identification of potential therapeutic targets by gene-expression profiling in pancreatic endocrine tumors. Gastroenterology 2006; 131: 1597- 1610.
77. Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, et al: MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006; 24: 4677-4684.
78. Di Florio A, Capurso G, Milione M, Panzuto F, Geremia R, Delle Fave G, et al: Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumour cells. Endocr Relat Cancer 2007; 14: 111-124.
79. Hansel DE, Rahman A, Hermans J, de Krijger RR, Ashfaq R, Yeo CJ, et al: Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Mod Pathol 2003; 16: 652-659.
80. Hansel DE, House MG, Ashfaq R, Rahman A, Yeo CJ, Maitra A: MAGE1 is expressed by a subset of pancreatic endocrine neoplasms and associated lymph node and liver metastases. Int J Gastrointest Cancer 2003; 33: 141- 147.
81. Karkkainen MJ, Petrova TV: Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 2000; 19: 5598-5605.
82. Rahman A, Maitra A, Ashfaq R, Yeo CJ, Cameron JL, Hansel DE: Loss of p27 nuclear expression in a prognostically favorable subset of well-differentiated pancreatic endocrine neoplasms. Am J Clin Pathol 2003; 120: 685-690.
83. Lindberg D, Hessman O, Akerstrom G, Westin G: Cyclin-dependent kinase 4 (CDK4) expression in pancreatic endocrine tumors. Neuroendocrinology 2007; 86: 112-118.
84. Fjallskog ML, Hessman O, Eriksson B, Janson ET: Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncol 2007; 46: 741- 746.
85. Borka K, Kaliszky P, Szabo E, Lotz G, Kupcsulik P, Schaff Z, et al: Claudin expression in pancreatic endocrine tumors as compared with ductal adenocarcinomas. Virchows Arch 2007; 450: 549-557.
86. Takahashi Y, Akishima-Fukasawa Y, Kobayashi N, Sano T, Kosuge T, Nimura Y, et al: Prognostic value of tumor architecture, tumor- associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors. Clin Cancer Res 2007; 13: 187-196.
87. Dalai I, Missiaglia E, Barbi S, Butturini G, Doglioni C, Falconi M, et al: Low expression of ARHI is associated with shorter progression- free survival in pancreatic endocrine tumors. Neoplasia 2007; 9: 181-183.
88. Missiaglia E, Moore PS, Williamson J, Lemoine NR, Falconi M, Zamboni G, et al: Sex chromosome anomalies in pancreatic endocrine tumors. Int J Cancer 2002; 98: 532- 538.
89. Chang MC, Xiao S, Nose V: Clinicopathologic and immunohistochemical correlation in sporadic pancreatic endocrine tumors: possible roles of utrophin and cyclin D1 in malignant progression. Hum Pathol 2007; 38: 732-740.
90. Mourra N, Couvelard A, Tiret E, Olschwang S, Flejou JF: Clusterin is highly expressed in pancreatic endocrine tumours but not in solid pseudopapillary tumours. Histopathology 2007; 50: 331-337.
91. Ekeblad S, Lejonklou MH, Grimfjard P, Johansson T, Eriksson B, Grimelius L, et al: Co-expression of ghrelin and its receptor in pancreatic endocrine tumours. Clin Endocrinol (Oxf) 2007; 66: 115-122.
92. House MG, Herman JG, Guo MZ, Hooker CM, Schulick RD, Lillemoe KD, et al: Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg 2003; 238: 423-431; discussion 431-432.
93. Cecconi D, Donadelli M, Rinalducci S, Zolla L, Scupoli MT, Scarpa A, et al: Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A. Proteomics 2007; 7: 1644-1653.
94. Chen M, Rahman L, Voeller D, Kastanos E, Yang SX, Feigenbaum L, et al: Transgenic expression of human thymidylate synthase accelerates the development of hyperplasia and tumors in the endocrine pancreas. Oncogene 2007; 26: 4817-4824.
95. Klimstra DS, Heffess CS, Oertel JE, Rosai J: Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. Am J Surg Pathol 1992; 16: 815-837.
96. Klimstra DS, Wenig BM, Adair CF, Heffess CS: Pancreatoblastoma. A clinicopathologic study and review of the literature. Am J Surg Pathol 1995; 19: 1371-1389.
97. Hoorens A, Gebhard F, Kraft K, Lemoine NR, Kloppel G: Pancreatoblastoma in an adult: its separation from acinar cell carcinoma. Virchows Arch 1994; 424: 485-490.
98. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, et al: K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994; 54: 1556-1560.
99. Cao D, Maitra A, Saavedra JA, Klimstra DS, Adsay NV, Hruban RH: Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathways. Mod Pathol 2005; 18: 752-761.
100. Lin YC, Lee PH, Yao YT, Hsiao JK, Sheu JC, Chen CH: Alpha-fetoprotein- producing pancreatic acinar cell carcinoma. J Formos Med Assoc 2007; 106: 669-672.
101. Kolb-van Harten P, Rosien U, Kloppel G, Layer P: Pancreatic acinar cell carcinoma with excessive alpha-fetoprotein expression. Pancreatology 2007; 7: 370-372.
102. Saif MW: Pancreatoblastoma. JOP 2007; 8: 55-63.
103. Abraham SC, Wu TT, Hruban RH, Lee JH, Yeo CJ, Conlon K, et al: Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol 2002; 160: 953-962.
104. Abraham SC, Wu TT, Klimstra DS, Finn LS, Lee JH, Yeo CJ, et al: Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas: frequent alterations in the APC/beta-catenin pathway and chromosome 11p. Am J Pathol 2001; 159: 1619- 1627.
105. Kerr NJ, Chun YH, Yun K, Heathcott RW, Reeve AE, Sullivan MJ: Pancreatoblastoma is associated with chromosome 11p loss of heterozygosity and IGF2 overexpression. Med Pediatr Oncol 2002; 39: 52-54.
106. Tanaka Y, Kato K, Notohara K, Nakatani Y, Miyake T, Ijiri R, et al: Significance of aberrant (cytoplasmic/nuclear) expression of beta-catenin in pancreatoblastoma. J Pathol 2003; 199: 185-190.
107. Nishimata S, Kato K, Tanaka M, Ijiri R, Toyoda Y, Kigasawa H, et al: Expression pattern of keratin subclasses in pancreatoblastoma with special emphasis on squamoid corpuscles. Pathol Int 2005; 55: 297- 302.
108. Wong IH, Chan J, Wong J, Tam PK: Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia. Clin Cancer Res 2004; 10: 994-1002.
109. Tang LH, Aydin H, Brennan MF, Klimstra DS: Clinically aggressive solid pseudopapillary tumors of the pancreas: a report of two cases with components of undifferentiated carcinoma and a comparative clinicopathologic analysis of 34 conventional cases. Am J Surg Pathol 2005; 29: 512-519.
110. Santini D, Poli F, Lega S: Solid-papillary tumors of the pancreas: histopathology. JOP 2006; 7: 131-136.
111. Papavramidis T, Papavramidis S: Solid pseudopapillary tumors of the pancreas: review of 718 patients reported in English literature. J Am Coll Surg 2005; 200: 965- 972.
112. Abraham SC, Klimstra DS, Wilentz RE, Yeo CJ, Conlon K, Brennan M, et al: Solidpseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol 2002; 160: 1361-1369.
113. Min Kim S, Sun CD, Park KC, Kim HG, Lee WJ, Choi SH: Accumulation of beta-catenin protein, mutations in exon-3 of the betacatenin gene and a loss of heterozygosity of 5q22 in solid pseudopapillary tumor of the pancreas. J Surg Oncol 2006; 94: 418-425.
114. Tanaka Y, Kato K, Notohara K, Hojo H, Ijiri R, Miyake T, et al: Frequent beta-catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solid-pseudopapillary neoplasm. Cancer Res 2001; 61: 8401- 8404.
115. El-Bahrawy MA, Rowan A, Horncastle D, Tomlinson I, Theis BA, Russell RC, et al: Ecadherin/ catenin complex status in solid pseudopapillary tumor of the pancreas. Am J Surg Pathol 2008; 32: 1-7.
116. Kim MJ, Jang SJ, Yu E: Loss of E-cadherin and cytoplasmic-nuclear expression of beta-catenin are the most useful immunoprofiles in the diagnosis of solid-pseudopapillary neoplasm of the pancreas. Hum Pathol 2008; 39: 251-258.
117. Tang WW, Stelter AA, French S, Shen S, Qiu S, Venegas R, et al: Loss of cell-adhesion molecule complexes in solid pseudopapillary tumor of pancreas. Mod Pathol 2007; 20: 509-513.
118. Serra S, Salahshor S, Fagih M, Niakosari F, Radhi JM, Chetty R: Nuclear expression of E-cadherin in solid pseudopapillary tumors of the pancreas. JOP 2007; 8: 296-303.
119. Audard V, Cavard C, Richa H, Infante M, Couvelard A, Sauvanet A, et al: Impaired E-cadherin expression and glutamine synthetase overexpression in solid pseudopapillary neoplasm of the pancreas. Pancreas 2008; 36: 80-83.
120. Tiemann K, Heitling U, Kosmahl M, Kloppel G: Solid pseudopapillary neoplasms of the pancreas show an interruption of the Wnt-signaling pathway and express gene products of 11q. Mod Pathol 2007; 20: 955- 960.
121. Geers C, Moulin P, Gigot JF, Weynand B, Deprez P, Rahier J, et al: Solid and pseudopapillary tumor of the pancreas - review and new insights into pathogenesis. Am J Surg Pathol 2006; 30: 1243-1249.